Annual Cash & Cash Equivalents
$1.27 B
-$3.01 B-70.31%
01 December 2023
Summary:
Sinovac Biotech annual cash & cash equivalents is currently $1.27 billion, with the most recent change of -$3.01 billion (-70.31%) on 01 December 2023. During the last 3 years, it has risen by +$229.12 million (+22.01%). SVA annual cash & cash equivalents is now -89.06% below its all-time high of $11.61 billion, reached on 31 December 2021.SVA Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$1.07 B
-$197.78 M-15.57%
01 June 2024
Summary:
Sinovac Biotech quarterly cash and cash equivalents is currently $1.07 billion, with the most recent change of -$197.78 million (-15.57%) on 01 June 2024. Over the past year, it has dropped by -$197.78 million (-15.57%). SVA quarterly cash and cash equivalents is now -90.76% below its all-time high of $11.61 billion, reached on 31 December 2021.SVA Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SVA Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | - | -15.6% |
| 3 y3 years | +22.0% | -84.3% |
| 5 y5 years | +703.0% | +584.4% |
SVA Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -89.1% | +22.0% | -90.8% | at low |
| 5 y | 5 years | -89.1% | +731.7% | -90.8% | +658.7% |
| alltime | all time | -89.1% | >+9999.0% | -90.8% | >+9999.0% |
Sinovac Biotech Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| June 2024 | - | $1.07 B(-15.6%) |
| Dec 2023 | $1.27 B(-70.3%) | $1.27 B(-22.7%) |
| June 2023 | - | $1.64 B(-61.6%) |
| Dec 2022 | $4.28 B(-63.1%) | $4.28 B(-37.6%) |
| June 2022 | - | $6.86 B(-40.9%) |
| Dec 2021 | $11.61 B(+1015.2%) | $11.61 B(+69.6%) |
| June 2021 | - | $6.84 B(+557.4%) |
| Dec 2020 | $1.04 B(+581.7%) | $1.04 B(+592.9%) |
| Sept 2020 | - | $150.24 M(+6.3%) |
| June 2020 | - | $141.34 M(-14.5%) |
| Mar 2020 | - | $165.34 M(+8.3%) |
| Dec 2019 | $152.72 M(-3.4%) | $152.72 M(-2.5%) |
| Sept 2019 | - | $156.70 M(+3.3%) |
| June 2019 | - | $151.69 M(+1.8%) |
| Mar 2019 | - | $149.05 M(-5.8%) |
| Dec 2018 | $158.17 M(+38.2%) | $158.17 M(+79.5%) |
| June 2018 | - | $88.11 M(-23.0%) |
| Dec 2017 | $114.42 M(+83.3%) | $114.42 M(+108.1%) |
| June 2017 | - | $54.98 M(-11.9%) |
| Dec 2016 | $62.43 M(-2.2%) | $62.43 M(+14.9%) |
| Sept 2016 | - | $54.32 M(+10.4%) |
| June 2016 | - | $49.22 M(-21.3%) |
| Mar 2016 | - | $62.51 M(-2.1%) |
| Dec 2015 | $63.83 M(-30.1%) | $63.83 M(+17.4%) |
| Sept 2015 | - | $54.36 M(-16.1%) |
| June 2015 | - | $64.76 M(+2.7%) |
| Mar 2015 | - | $63.07 M(-30.9%) |
| Dec 2014 | $91.29 M(-14.9%) | $91.29 M(-3.2%) |
| Sept 2014 | - | $94.35 M(+5.3%) |
| June 2014 | - | $89.63 M(-11.8%) |
| Mar 2014 | - | $101.65 M(-5.2%) |
| Dec 2013 | $107.24 M(+17.5%) | $107.24 M(+20.5%) |
| Sept 2013 | - | $89.03 M(-3.3%) |
| June 2013 | - | $92.05 M(+0.5%) |
| Mar 2013 | - | $91.56 M(+0.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2012 | $91.24 M(-12.5%) | $91.24 M(+11.3%) |
| Sept 2012 | - | $81.96 M(-8.4%) |
| June 2012 | - | $89.44 M(-5.3%) |
| Mar 2012 | - | $94.49 M(-9.4%) |
| Dec 2011 | $104.29 M(+2.7%) | $104.29 M(+69.9%) |
| Sept 2011 | - | $61.40 M(-12.6%) |
| June 2011 | - | $70.29 M(-22.7%) |
| Mar 2011 | - | $90.98 M(-10.4%) |
| Dec 2010 | $101.59 M(+35.5%) | $101.59 M(+20.2%) |
| Sept 2010 | - | $84.50 M(-10.7%) |
| June 2010 | - | $94.64 M(-20.4%) |
| Mar 2010 | - | $118.93 M(+58.7%) |
| Dec 2009 | $74.95 M(+127.9%) | $74.95 M(+60.9%) |
| Sept 2009 | - | $46.58 M(-0.3%) |
| June 2009 | - | $46.70 M(+100.4%) |
| Mar 2009 | - | $23.31 M(-29.1%) |
| Dec 2008 | $32.89 M(+92.7%) | $32.89 M(+60.0%) |
| Sept 2008 | - | $20.55 M(+9.2%) |
| June 2008 | - | $18.82 M(-8.5%) |
| Mar 2008 | - | $20.58 M(+20.5%) |
| Dec 2007 | $17.07 M(+84.6%) | $17.07 M(+76.4%) |
| Sept 2007 | - | $9.68 M(+4.2%) |
| June 2007 | - | $9.28 M(+0.4%) |
| Dec 2006 | $9.25 M(+25.8%) | $9.25 M(+30.4%) |
| June 2006 | - | $7.09 M(-3.5%) |
| Dec 2005 | $7.35 M(+182.3%) | $7.35 M(+447.9%) |
| June 2005 | - | $1.34 M(-48.5%) |
| Dec 2004 | $2.61 M(+83.5%) | $2.61 M(+23.0%) |
| Sept 2004 | - | $2.12 M(-29.8%) |
| June 2004 | - | $3.02 M(+112.6%) |
| Dec 2003 | $1.42 M(+1973.0%) | $1.42 M |
| Apr 2002 | $68.50 K(+105.7%) | - |
| Apr 2001 | $33.30 K(-74.6%) | - |
| Apr 2000 | $131.30 K(+291.9%) | - |
| Apr 1999 | $33.50 K | - |
FAQ
- What is Sinovac Biotech annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Sinovac Biotech?
- What is Sinovac Biotech quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Sinovac Biotech?
- What is Sinovac Biotech quarterly cash and cash equivalents year-on-year change?
What is Sinovac Biotech annual cash & cash equivalents?
The current annual cash & cash equivalents of SVA is $1.27 B
What is the all time high annual cash & cash equivalents for Sinovac Biotech?
Sinovac Biotech all-time high annual cash & cash equivalents is $11.61 B
What is Sinovac Biotech quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of SVA is $1.07 B
What is the all time high quarterly cash and cash equivalents for Sinovac Biotech?
Sinovac Biotech all-time high quarterly cash and cash equivalents is $11.61 B
What is Sinovac Biotech quarterly cash and cash equivalents year-on-year change?
Over the past year, SVA quarterly cash and cash equivalents has changed by -$197.78 M (-15.57%)